|
TA read The box (yellow) is our accumulation range (~$1.00–$1.70). tons of back-and-forth while weak hands got rinsed. Then the pop = a Sign of Strength (SOS) through the old $1.70 lid, follow-through over $2, and now we’re sprinting into Phase D (markup). What usually comes next in Phase D: a “back-up” / retest that checks if new buyers defend. for this 1h chart, the spots to watch: $2.30–$2.40 (shallow, healthy retest) $2.10–$2.20 (deeper check of the breakout shelf) $1.70 is the big, must-hold line from the base. Translation: trend is up; a controlled pullback with lighter volume would be normal and buyable. a heavy-volume puke below $2.10 says “failed breakout… back to the range.” Candlesticks The last leg is basically bullish marubozu-style candles (long real bodies, buyers in charge). RSI is hot (70s) and MACD is ripping, so a breather wouldn’t surprise anyone. what to look for: healthy pause: 3-5 candles of small bodies/spinning tops or a tight flag, volume cools, then a full-bodied green close > $2.60 -> continuation. warning signs: a shooting star/doji near $2.55–$2.65 with elevated volume, or a bearish engulfing that closes back under ~$2.35 -> likely back-test toward $2.20. levels (keep it simple) resistance: $2.55–$2.65 now; above that $2.90–$3.10 is the next supply zone. support: $2.30–$2.40 (first buy-the-dip zone), then $2.10–$2.20 (shelf), and $1.70 (major). Why the story fits the tape Record consumables again in Q3 ($21.3M, ~55% of revenue) + non-GAAP GM 42% (best since 2022). Q4 guided ~+10% QoQ; SPRQ-Nx beta starting now (multi-use SMRT Cells; sub-$300/genome target) sets up a usage kicker in 2026. Clinical & cohort demand (China CNDx approval, PureTarget panels, LLFS, Korean Pangenome) = multi-year, consumables-heavy runways. That’s classic wyckoff: the company built cause during the base; the breakout says the market is starting to discount the effect. submitted by /u/Brilliant_Builder697 to r/PACB |